ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

2:00PM-3:30PM: Abstract Number: 0758

Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0747

Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0782

Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies

Abstracts: SLE – Treatment I: Renal

2:00PM-3:30PM: Abstract Number: 0767

Current Musculoskeletal Ultrasound Practices of 12 Years of past Participants of a 10-Months Rheumatology Ultrasound Training Program (Ultrasound School of North American Rheumatologists)

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0736

Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics

Abstracts: Genetics, Genomics & Proteomics

2:00PM-3:30PM: Abstract Number: 0774

Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0735

Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis

Abstracts: Genetics, Genomics & Proteomics

2:00PM-3:30PM: Abstract Number: 0759

Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0769

Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0775

Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

2:00PM-3:30PM: Abstract Number: 0776

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

2:00PM-3:30PM: Abstract Number: 0761

EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0791

Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0753

Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0733

Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

Abstracts: Genetics, Genomics & Proteomics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].